Reactivity of monoclonal antibodies leu 1 and OKT1 with malignant human lymphoid cells. Correlation with conventional cell markers

Abstract

This study delineated the distribution of reactivity of malignant human lymphoid cells with monoclonal antibodies Leu 1 and OKT1, and correlated this expression with that of conventional lymphoid cell markers. The presence of Leu 1 on benign lymph nodal T‐cells and its absence from benign lymph nodal B‐cells was confirmed. Twenty‐two T‐cell neoplasms, expressing a variety of intrathymic and mature peripheral phenotypes, expressed Leu 1, but this expression was heterogeneous with respect to percent‐positive cells and antigenic density, and appeared to correlate with stages of T‐cell differentiation. This study demonstrated the expression of Leu 1 by 33 of 36 cases of B‐CLL, by 10 of 15 cases of the closely allied small lymphocytic cell lymphoma, and by 9 of 29 follicular center‐cell lymphomas. This included B‐cell malignancies of each surface immunoglobulin isotype, and some cases associated with a monoclonal protein spike. Leu 1 was not expressed by myeloma plasma cells, and was absent from non‐B, non‐T acute lymphoblastic leukemia cells in each of 15 cases studied. Finally, Leu 1 and OKT1 were expressed in parallel, with respect to percent‐positive cells and staining intensity, on benign and malignant T‐cells, and on malignant B‐cells, wherever studied. Possible explanations for this shared antigen are the existence of a minor Leu 1+ B‐cell subset, a transformation‐associated event, or glycosylation.

Membrane phenotypic studies in B cell lymphoproliferative disorders.

“…An association between CALLA positive cases and the absence of Ti expression has been suggested previously,'" 1833 although others have reported a variable expression of Leul/OKT1 positive cells in follicular lymphomas.34 35 In conclusion, the results of this study suggest that, even with a limited range of immunological investigations, some consistency in classification of disease may be attained. The phenotypic pattern represented by most cases of CLL was clearly shown to be: low density SIg; increased expression of MRBC receptors; the presence of membrane TU1, and, finally, the absence of significant CALLA and FMC7.…”

T-lymphocyte subpopulations in B-cell-derived non-hodgkin's lymphomas and hodgkin's disease

“…Representative portions of 91 lymph nodes and 26 ocular adnexal lymphoid neoplasms were freshly obtained under sterile conditions from the surgical specimens of patients undergoing evaluation for possible malignant lymphoma. The lymph node biopsies were classified by conventional histopathologic criteria as non-Hodgkin's lymphoma (5 l), benign lymphoid hyperplasia (25) or Hodgkin's disease ( 15). The ocular adnexal biopsies were classified as benign lymphoid hyperplasia ( 10) or non-Hodgkin's lymphoma (16) according to previously published histopathologic criteria."…”

Detection of light chain restriction in chronic B-lymphoid leukaemia and B-non-Hodgkin's lymphoma

“…The assessment of monoclonal light chain immunoglobulins in cells suspensions, aspirates and tissue sections of lymph nodes and blood lymphocytes has been made possible by immunofluorescent microscopy, flow cytometry and immunocytology. Studies of B-non-Hodgkin's lymphomas of low and high malignancy using suspension immunofluorescence of lymph node cells with polyclonal antibodies (Aisenberg et al 1983;Cossman et al 1984;Knowles et al 1983) and irnmunocytological investigation of lymph node aspirates with a monoclonal antibody (Oertel et al 1988) demonstrated that the majority of B-lymphomas showed monoclonal light chain immunoglobulins. Immunohistological studies of frozen sections of B-cell lymphomas of low malignancy using polyclonal antibodies showed in the majority of cases the monotypie of the light chains.…”